DNA methylation biomarkers-based pan-cancer classifier: predictive modeling for cancer classification

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: 0.90 balanced accuracy (90%)

• Primary Outcome: Balanced accuracy for pan-cancer classification

• Nnt Or Sensitivity: CNS tumor classifier: 0.94 balanced accuracy; uses 1,208 CpG sites

• Confidence Interval: Not reported

Clinical Application

Requires DNA methylation profiling capability and bioinformatics infrastructure; web platform available Could complement existing pathology services; would require TGA approval for diagnostic use; potential PBS consideration for complex cases Patients requiring cancer classification or differential diagnosis, particularly for challenging cases

Abstract

BACKGROUND: Machine-learning (ML) driven molecular diagnostics based on omics data has a potential to revolutionize personalized medicine. However, implementation of ML into diagnostic protocols is hindered by methodological challenges which often lead to inflated performance assessment of models during development followed by poor performance of these models in implementation phase. Here, we aimed to develop and validate a pan-cancer classification framework based on DNA methylation data, that addresses methodological challenges of omics data powered ML. METHODS: We curated a primary dataset of DNA methylation profiles for 10756 samples, that included 54 healthy and cancer tissue types and validation dataset comprising data for 2306 samples from 28 independent studies. The classification framework was build using custom biomarkers selection strategy based on effect size metric that considers variance and class imbalance. The ML models were trained, tuned and evaluated using nested cross-validation approach. Local outlier factor algorithm was built into the inference pipelines to identify and filter samples displaying technical or biological anomalies. Additionally, for methodological validation of our framework we used methylation profiles for 3905 central nervous system (CNS) tumors. RESULTS: We found that relatively simple ML models outperformed complex algorithms such as deep neural network. A logistic regression classifier achieved a balanced accuracy (BACC) of 0.90 to classify 54 cancer and healthy tissue types using methylation levels at 1208 CpG sites. Similarly, our CNS tumor classifier also based on logistic regression algorithm reached a BACC of 0.94 across 59 CNS tumor subtypes. The anomaly filtering improved performance across all categories of samples tested. CONCLUSIONS: Our study demonstrates that DNA methylation profiling, when combined with carefully controlled ML practices allows for development of robust solutions that might substantially increase the efficacy of oncological diagnosis. Finally, we deployed our inference pipelines for public access via secure web platform - https://opp.pum.edu.pl/ .

References

1. 1.Bińkowski, J., & Wojdacz, T. K. (2026). DNA methylation biomarkers-based pan-cancer classifier: predictive modeling for cancer classification. Genome Medicine. https://doi.org/10.1186/s13059-018-1448-7